Alexion Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) have received an average rating of “Buy” from the eighteen analysts that are covering the stock, StockRatingsNetwork reports. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $183.00.
Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 170.00 on Thursday. Alexion Pharmaceuticals has a 1-year low of $100.89 and a 1-year high of $185.43. The stock has a 50-day moving average of $163.1 and a 200-day moving average of $162.8. The company has a market cap of $33.629 billion and a price-to-earnings ratio of 84.58.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 24th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.
A number of research firms have recently commented on ALXN. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00.
In other Alexion Pharmaceuticals news, CEO Leonard Bell sold 70,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $167.99, for a total transaction of $11,759,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.